ImClone Systems News

Martha Stewart checked into the minimum-security women's prison in Alderson, W. Va., about 5:55 a.m. Friday to begin her sentence for lying about a 2001 sale of ImClone Systems Inc.

Genzyme Corp. is dropping further work on its advanced phosphate binder - the product expected to save the Cambridge, Mass.-based firm's renal franchise from the looming patent cliff - after it failed to show improvement over Renvela in a Phase II/III trial, leaving analysts and investors to wonder what's next for the big biotech, which has ...

BARRIE McKENNA Published on Tuesday, Nov. 17, 2009 12:00AM EST Last updated on Tuesday, Nov.

Rule Breaker . As long as I live, I'll never forget the day I first heard those two words.

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

Eli Lilly and Co. swung to a profit in its third quarter, the Indianapolis-based company reported this morning.

A restructuring Eli Lilly and Co. , which faces patent losses on 80% of its key drugs by 2013, will report third-quarter earnings on Wednesday.

Apologizing to supporters for "a small personal matter" that "became an almost fatal circus event," Martha Stewart was sentenced yesterday to five months in prison and five months of home detention for the stock-trading cover-up that upended her life, her company and her finely groomed image.

Ilhavo, Portugal a ' 28/09/2009 a ' SADIF Investment Analytics, announces a new summary due diligence report covering ImClone Systems Incorporated .

More Lilly will reorganize and cut jobs to pare costs September 14, 2009 10:23 AM EDT NEW YORK - Drugmaker Eli Lilly & Co.

ImClone Systems sought to register the mark STRENGTH IN DATA for advertising and promotional publications in the health care field.

Although a controversial topic, activist hedge funds and private equity firms typically use a small equity stake in an underperforming company to put public pressure on its management and board of directors with the goal of increasing stakeholder value through cost cutting, changes in corporate strategy or management, capital restructuring, asset ...

Dyax Corp. announced today successful advancement into Phase 1 clinical trials of two candidates identified using Dyaxa s proprietary phage display technology by licensees of the Companya s Licensing and Funded Research Program .

Biotechnology company Dyax Corp. said Wednesday it received a $1.5 million payment as Eli Lilly & Co.

Biotechnology company Dyax Corp. said Wednesday it received a $1.5 million payment as Eli Lilly & Co.

Cempra Pharmaceuticals has added some high-powered clout to its board of directors in the form of ImClone Systems CEO John Johnson.

Eli Lilly and Company announced today during a lease signing event that it has become the first tenant of New York City's new Alexandria Center for Science and Technology at East River Science Park, a development that shows tangible evidence that New York is positioning itself to become a hub for biopharmaceutical research.

A state-of-the-art science center being built on Manhattan's East Side has attracted its first tenant.

BioMedReports.com , the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

On the same day that Eli Lilly was talking up the commercial prospects of pipeline candidates acquired through its $6.5bn purchase of ImClone Systems last year, a deal which hijacked Bristol-Myers Squibb's plans to get its hands on an antibody technology platform, BMS has finally fulfilled its original objective with a $2.4bn swoop on Medarex.